Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology
Abstract Background Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Unfortunately, prospective randomized controlled phase 3 studies (AVAglio and Radiation Therapy Oncology Group 0825 in newly diagnosed, European Organisation for Resear...
Gespeichert in:
| Veröffentlicht in: | Neuro-oncology practice 2020-01, Vol.7 (1), p.52-58 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 58 |
|---|---|
| container_issue | 1 |
| container_start_page | 52 |
| container_title | Neuro-oncology practice |
| container_volume | 7 |
| creator | Ranjan, Surabhi Skorupan, Nebojša Ye, Xiaobu Sivakumar, Ananyaa Yankulina, Olga Kamson, David Grossman, Stuart A Dzaye, Omar Holdhoff, Matthias |
| description | Abstract
Background
Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Unfortunately, prospective randomized controlled phase 3 studies (AVAglio and Radiation Therapy Oncology Group 0825 in newly diagnosed, European Organisation for Research and Treatment of Cancer 26101 in rGBM) failed to show an overall survival benefit with BEV added to standard therapy. In light of these data, we aimed to capture current utilization patterns and perceived value of BEV in the treatment of GBM among experts in the field.
Methods
An online questionnaire comprising 14 multiple choice questions was sent out in spring 2017 to 207 oncologists/neuro-oncologists treating patients with GBM at all National Cancer Institute–designated cancer centers in the United States.
Results
Sixty-two of 207 (30%) invitees responded (by training, 70% neuro-oncologists, 20% medical oncologists, 10% pediatric oncologists/neuro-oncologists). Participants reported use of BEV most frequently in rGBM for control of edema (85% of respondents) and/or when no other treatment options were available (68%). BEV is rarely used in newly diagnosed GBM ( |
| doi_str_mv | 10.1093/nop/npz022 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7104881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/nop/npz022</oup_id><sourcerecordid>10.1093/nop/npz022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-4ebec359c576ee3e541d4b48dc2877e611ebd6cd3f698faddbfe08c527b941f73</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxYMo7rLuxQ8guXgRqknTNqkHQRb_wYIe9FySdLobbZOStKu7n97K6qIXTzPwfu_N8BA6puSckpxdWNde2HZD4ngPjWOSJlGcinR_t3M-QtMQXgkhlGWUifwQjVg8CLFIxujtSXYdeBuwq7CCldRm0zdS4T4ANha3sjNgu4DfTbfEi9o4VcvQuUZeYmmxs7WxgEPvV7DGsnF2geGjBT84BreF3rvIWe1qt1gfoYNK1gGm33OCXm5vnmf30fzx7mF2PY80y3gXJaBAszTXKc8AGKQJLROViFLHgnPIKAVVZrpkVZaLSpalqoAIncZc5QmtOJugq21u26sGSj3872VdtN400q8LJ03xV7FmWSzcquCUJELQIeBsG6C9C8FDtfNSUny1XgytF9vWB_jk97Ud-tPxAJxuAde3_wV9AtMDkAU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ranjan, Surabhi ; Skorupan, Nebojša ; Ye, Xiaobu ; Sivakumar, Ananyaa ; Yankulina, Olga ; Kamson, David ; Grossman, Stuart A ; Dzaye, Omar ; Holdhoff, Matthias</creator><creatorcontrib>Ranjan, Surabhi ; Skorupan, Nebojša ; Ye, Xiaobu ; Sivakumar, Ananyaa ; Yankulina, Olga ; Kamson, David ; Grossman, Stuart A ; Dzaye, Omar ; Holdhoff, Matthias</creatorcontrib><description>Abstract
Background
Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Unfortunately, prospective randomized controlled phase 3 studies (AVAglio and Radiation Therapy Oncology Group 0825 in newly diagnosed, European Organisation for Research and Treatment of Cancer 26101 in rGBM) failed to show an overall survival benefit with BEV added to standard therapy. In light of these data, we aimed to capture current utilization patterns and perceived value of BEV in the treatment of GBM among experts in the field.
Methods
An online questionnaire comprising 14 multiple choice questions was sent out in spring 2017 to 207 oncologists/neuro-oncologists treating patients with GBM at all National Cancer Institute–designated cancer centers in the United States.
Results
Sixty-two of 207 (30%) invitees responded (by training, 70% neuro-oncologists, 20% medical oncologists, 10% pediatric oncologists/neuro-oncologists). Participants reported use of BEV most frequently in rGBM for control of edema (85% of respondents) and/or when no other treatment options were available (68%). BEV is rarely used in newly diagnosed GBM (<5% of cases by 78% respondents and in 5% to 10% cases by 15% respondents). Sixty-six percent of participants indicated that they thought BEV improved symptoms, 30% that it improved symptoms and survival, 3% that it had no benefit in GBM patients.
Conclusion
In this cross-sectional online survey we found that among neuro-oncology experts in the United States in 2017, BEV is predominantly utilized in select patients with rGBM, and is only rarely used in a small subgroup of patients with newly diagnosed GBM for control of edema. The low response rate may have introduced a nonresponse bias.</description><identifier>ISSN: 2054-2577</identifier><identifier>EISSN: 2054-2585</identifier><identifier>DOI: 10.1093/nop/npz022</identifier><identifier>PMID: 32257284</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Original</subject><ispartof>Neuro-oncology practice, 2020-01, Vol.7 (1), p.52-58</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c367t-4ebec359c576ee3e541d4b48dc2877e611ebd6cd3f698faddbfe08c527b941f73</cites><orcidid>0000-0001-9483-3510</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104881/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104881/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1584,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32257284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ranjan, Surabhi</creatorcontrib><creatorcontrib>Skorupan, Nebojša</creatorcontrib><creatorcontrib>Ye, Xiaobu</creatorcontrib><creatorcontrib>Sivakumar, Ananyaa</creatorcontrib><creatorcontrib>Yankulina, Olga</creatorcontrib><creatorcontrib>Kamson, David</creatorcontrib><creatorcontrib>Grossman, Stuart A</creatorcontrib><creatorcontrib>Dzaye, Omar</creatorcontrib><creatorcontrib>Holdhoff, Matthias</creatorcontrib><title>Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology</title><title>Neuro-oncology practice</title><addtitle>Neurooncol Pract</addtitle><description>Abstract
Background
Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Unfortunately, prospective randomized controlled phase 3 studies (AVAglio and Radiation Therapy Oncology Group 0825 in newly diagnosed, European Organisation for Research and Treatment of Cancer 26101 in rGBM) failed to show an overall survival benefit with BEV added to standard therapy. In light of these data, we aimed to capture current utilization patterns and perceived value of BEV in the treatment of GBM among experts in the field.
Methods
An online questionnaire comprising 14 multiple choice questions was sent out in spring 2017 to 207 oncologists/neuro-oncologists treating patients with GBM at all National Cancer Institute–designated cancer centers in the United States.
Results
Sixty-two of 207 (30%) invitees responded (by training, 70% neuro-oncologists, 20% medical oncologists, 10% pediatric oncologists/neuro-oncologists). Participants reported use of BEV most frequently in rGBM for control of edema (85% of respondents) and/or when no other treatment options were available (68%). BEV is rarely used in newly diagnosed GBM (<5% of cases by 78% respondents and in 5% to 10% cases by 15% respondents). Sixty-six percent of participants indicated that they thought BEV improved symptoms, 30% that it improved symptoms and survival, 3% that it had no benefit in GBM patients.
Conclusion
In this cross-sectional online survey we found that among neuro-oncology experts in the United States in 2017, BEV is predominantly utilized in select patients with rGBM, and is only rarely used in a small subgroup of patients with newly diagnosed GBM for control of edema. The low response rate may have introduced a nonresponse bias.</description><subject>Original</subject><issn>2054-2577</issn><issn>2054-2585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LxDAQxYMo7rLuxQ8guXgRqknTNqkHQRb_wYIe9FySdLobbZOStKu7n97K6qIXTzPwfu_N8BA6puSckpxdWNde2HZD4ngPjWOSJlGcinR_t3M-QtMQXgkhlGWUifwQjVg8CLFIxujtSXYdeBuwq7CCldRm0zdS4T4ANha3sjNgu4DfTbfEi9o4VcvQuUZeYmmxs7WxgEPvV7DGsnF2geGjBT84BreF3rvIWe1qt1gfoYNK1gGm33OCXm5vnmf30fzx7mF2PY80y3gXJaBAszTXKc8AGKQJLROViFLHgnPIKAVVZrpkVZaLSpalqoAIncZc5QmtOJugq21u26sGSj3872VdtN400q8LJ03xV7FmWSzcquCUJELQIeBsG6C9C8FDtfNSUny1XgytF9vWB_jk97Ud-tPxAJxuAde3_wV9AtMDkAU</recordid><startdate>20200131</startdate><enddate>20200131</enddate><creator>Ranjan, Surabhi</creator><creator>Skorupan, Nebojša</creator><creator>Ye, Xiaobu</creator><creator>Sivakumar, Ananyaa</creator><creator>Yankulina, Olga</creator><creator>Kamson, David</creator><creator>Grossman, Stuart A</creator><creator>Dzaye, Omar</creator><creator>Holdhoff, Matthias</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9483-3510</orcidid></search><sort><creationdate>20200131</creationdate><title>Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology</title><author>Ranjan, Surabhi ; Skorupan, Nebojša ; Ye, Xiaobu ; Sivakumar, Ananyaa ; Yankulina, Olga ; Kamson, David ; Grossman, Stuart A ; Dzaye, Omar ; Holdhoff, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-4ebec359c576ee3e541d4b48dc2877e611ebd6cd3f698faddbfe08c527b941f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Ranjan, Surabhi</creatorcontrib><creatorcontrib>Skorupan, Nebojša</creatorcontrib><creatorcontrib>Ye, Xiaobu</creatorcontrib><creatorcontrib>Sivakumar, Ananyaa</creatorcontrib><creatorcontrib>Yankulina, Olga</creatorcontrib><creatorcontrib>Kamson, David</creatorcontrib><creatorcontrib>Grossman, Stuart A</creatorcontrib><creatorcontrib>Dzaye, Omar</creatorcontrib><creatorcontrib>Holdhoff, Matthias</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ranjan, Surabhi</au><au>Skorupan, Nebojša</au><au>Ye, Xiaobu</au><au>Sivakumar, Ananyaa</au><au>Yankulina, Olga</au><au>Kamson, David</au><au>Grossman, Stuart A</au><au>Dzaye, Omar</au><au>Holdhoff, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology</atitle><jtitle>Neuro-oncology practice</jtitle><addtitle>Neurooncol Pract</addtitle><date>2020-01-31</date><risdate>2020</risdate><volume>7</volume><issue>1</issue><spage>52</spage><epage>58</epage><pages>52-58</pages><issn>2054-2577</issn><eissn>2054-2585</eissn><abstract>Abstract
Background
Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Unfortunately, prospective randomized controlled phase 3 studies (AVAglio and Radiation Therapy Oncology Group 0825 in newly diagnosed, European Organisation for Research and Treatment of Cancer 26101 in rGBM) failed to show an overall survival benefit with BEV added to standard therapy. In light of these data, we aimed to capture current utilization patterns and perceived value of BEV in the treatment of GBM among experts in the field.
Methods
An online questionnaire comprising 14 multiple choice questions was sent out in spring 2017 to 207 oncologists/neuro-oncologists treating patients with GBM at all National Cancer Institute–designated cancer centers in the United States.
Results
Sixty-two of 207 (30%) invitees responded (by training, 70% neuro-oncologists, 20% medical oncologists, 10% pediatric oncologists/neuro-oncologists). Participants reported use of BEV most frequently in rGBM for control of edema (85% of respondents) and/or when no other treatment options were available (68%). BEV is rarely used in newly diagnosed GBM (<5% of cases by 78% respondents and in 5% to 10% cases by 15% respondents). Sixty-six percent of participants indicated that they thought BEV improved symptoms, 30% that it improved symptoms and survival, 3% that it had no benefit in GBM patients.
Conclusion
In this cross-sectional online survey we found that among neuro-oncology experts in the United States in 2017, BEV is predominantly utilized in select patients with rGBM, and is only rarely used in a small subgroup of patients with newly diagnosed GBM for control of edema. The low response rate may have introduced a nonresponse bias.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32257284</pmid><doi>10.1093/nop/npz022</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9483-3510</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2054-2577 |
| ispartof | Neuro-oncology practice, 2020-01, Vol.7 (1), p.52-58 |
| issn | 2054-2577 2054-2585 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7104881 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Original |
| title | Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A46%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patterns%20of%20bevacizumab%20use%20in%20patients%20with%20glioblastoma:%20an%20online%20survey%20among%20experts%20in%20neuro-oncology&rft.jtitle=Neuro-oncology%20practice&rft.au=Ranjan,%20Surabhi&rft.date=2020-01-31&rft.volume=7&rft.issue=1&rft.spage=52&rft.epage=58&rft.pages=52-58&rft.issn=2054-2577&rft.eissn=2054-2585&rft_id=info:doi/10.1093/nop/npz022&rft_dat=%3Coup_pubme%3E10.1093/nop/npz022%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32257284&rft_oup_id=10.1093/nop/npz022&rfr_iscdi=true |